Showing results (801-810 of 1,188) with videos related to

Sort By:
Pageof 119
Leukemia|June 21, 2020
The Clinical impact of PTPN11 mutations in adults with acute myeloid leukemiaMansour Alfayez, Ghayas C Issa, Keyur P Patel, et al.
Blood|October 11, 2003
Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylateDeborah A Thomas, Stefan Faderl, Jorge Cortes, et al.
Blood|September 17, 2014
TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patientsRafael Bejar, Allegra Lord, Kristen Stevenson, et al.
Leukemia Research|January 10, 2015
Mutational profiling of therapy-related myelodysplastic syndromes and acute myeloid leukemia by next generation sequencing, a comparison with de novo diseasesChi Young Ok, Keyur P Patel, Guillermo Garcia-Manero, et al.
Cancer|December 7, 2018
Validation of the 2017 European LeukemiaNet classification for acute myeloid leukemia with NPM1 and FLT3-internal tandem duplication genotypesPrajwal C Boddu, Tapan M Kadia, Guillermo Garcia-Manero, et al.
Cancer|October 15, 2016
Phase 2 study of low-dose clofarabine plus cytarabine for patients with higher-risk myelodysplastic syndrome who have relapsed or are refractory to hypomethylating agentsElias Jabbour, Stefan Faderl, Koji Sasaki, et al.
Leukemia Research|April 19, 2025
Safety and efficacy of the combination of azacitidine with venetoclax after hypomethylating agent failure in higher-risk myelodysplastic syndromeJulie S Braish, Guillermo Montalban-Bravo, Farhad Ravandi, et al.
Cancer|February 28, 2006
Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemiaDeborah A Thomas, Stefan Faderl, Susan O'Brien, et al.
Blood Cancer Journal|January 18, 2019
Late relapse in acute myeloid leukemia (AML): clonal evolution or therapy-related leukemia?Musa Yilmaz, Feng Wang, Sanam Loghavi, et al.
Cancer|April 6, 2021
Outcome of patients with chronic myeloid leukemia in lymphoid blastic phase and Philadelphia chromosome-positive acute lymphoblastic leukemia treated with hyper-CVAD and dasatinibKiyomi Morita, Hagop M Kantarjian, Koji Sasaki, et al.
Pageof 119